Fan Q B, Bian M L, Huang S Z, Lang J H, Ma J, Liu W S, Xu X Y
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing.
Chin Med J (Engl). 1994 Aug;107(8):589-93.
C-erbB-2(HER-2/neu) proto-oncogene is mainly expressed in epithelial tissue and activated due to its amplification. Amplification of the C-erbB-2 proto-oncogene has been associated with poor prognosis in human ovarian cancer. Our study was to examine whether amplification is more frequently observed in ovarian cancer, or it is associated with poor prognosis of human ovarian cancer in China. The DNA of ovarian cancers was extracted and consequently digested with restriction endonuclease EcoRI, electrophoresed in 0.8% agarose gels and blotted onto nitrocellulose filter with Southern transferring method. It was then hybridized with a 32P-labelled C-erbB-2 probe and subsequently underwent autoradiography. The result has shown that the C-erbB-2(HER-2/neu) gene was amplified in 8 of 26 human ovarian cancers (30.8%). The clinical data showed that all of the 8 cases with the amplified C-erbB-2 were in their advanced stage (III-IV). Five of the patients died from 2 to 4 months after operation. These data suggest that amplification of the C-erbB-2 gene may play a role in the pathogenesis of ovarian carcinoma; it is frequently observed in advanced ovarian cancer and is associated with poor prognosis for these patients.
C-erbB-2（HER-2/neu）原癌基因主要在上皮组织中表达，并因其扩增而被激活。C-erbB-2原癌基因的扩增与人类卵巢癌的不良预后相关。我们的研究旨在探讨在中国卵巢癌中是否更频繁地观察到扩增，或者它是否与人类卵巢癌的不良预后相关。提取卵巢癌的DNA，随后用限制性内切酶EcoRI消化，在0.8%琼脂糖凝胶中电泳，并用Southern转移法转移到硝酸纤维素滤膜上。然后用32P标记的C-erbB-2探针进行杂交，随后进行放射自显影。结果显示，26例人类卵巢癌中有8例（30.8%）C-erbB-2（HER-2/neu）基因扩增。临床数据显示，8例C-erbB-2扩增的病例均处于晚期（III-IV期）。其中5例患者在术后2至4个月死亡。这些数据表明，C-erbB-2基因的扩增可能在卵巢癌的发病机制中起作用；它在晚期卵巢癌中经常观察到，并且与这些患者的不良预后相关。
